Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Smoldering Multiple Myeloma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Lenalidomide 3PVX-410 vaccine 2siltuximab 1sargramostim 1poly ICLC 1dexamethasone acetate 1dexamethasone 21-phosphate 1citarinostat 1auricularum 1atezolizumab 1Receptors, Interleukin-6 1Monatide (IMS 3015) 1Interleukin 1 Receptor Antagonist Protein 1Emulsions 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Smoldering Multiple Myeloma × citarinostat × Clear all
NCT02886065 2026-03-13

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Massachusetts General Hospital

Phase 1 Active not recruiting
19 enrolled
Plasma cell

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡